Privia Health Group Inc. Common Stock (PRVA)

FairStock Score: 36/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Privia Health is a physician-enablement company: it supplies technology, administrative services, and a single-TIN medical group to help doctors focus on care. The business is growing. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $632.6 million versus $521.2 million in fiscal Q2 2025, and net income was $9.0 million versus $2.7 million. In FY2025, the year ended 2025-12-31, revenue was $2.1 billion and net income $22.9 million, so profits are real but very thin. FairStock's calculations at the 2026-10-13 close show a P/E of 98.41, P/B of 3.49, EV/EBITDA of 41.48, ROE of 4.31%, and ROCE of 2.03%. The balance sheet looks conservative with D/E of 0.01 and Altman Z-Score of 3.18. Free cash flow is $131.1 million, a 4.7% FCF yield. That is encouraging, but the Graham Number is $5.54, leaving a negative margin of safety of -290.79% against the $21.65 price. The PEG ratio of 0.42 offers a growth-based counterpoint, and FairStock classifies it as a TURNAROUND, returned to profit after a loss within the last three years. Piotroski F-Score is 5/9 and FairStock Score is 36/100. My read: an improving but low-margin intermediary with a promising growth story, priced as if that story must continue. Graham would demand a larger cushion; Buffett would want evidence of durable pricing power and higher returns on capital.

In plain English: Privia Health helps doctors' offices with software and back-office services so physicians can spend more time on patients. The company is growing sales quickly and has made small profits, but profit margins are thin and returns on money invested are modest. At $21.65, the stock looks expensive compared with those current profits and accounting value, so the price is relying on future growth.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer